Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vezocolmitide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ora, Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye D...
Brand Name : ST-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 29, 2023
Lead Product(s) : Vezocolmitide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ora, Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ST-113
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Glaukos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation
Details : Under the agreement, Glaukos gains exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113, a synthesized collagen mimetic peptide, drug candidate for neuroprotection in glaucoma.
Brand Name : ST-113
Molecule Type : Peptide
Upfront Cash : Undisclosed
October 18, 2023
Lead Product(s) : ST-113
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Glaukos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ST-100
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : AJU Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.
Details : ST-100 is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen.
Brand Name : ST-100
Molecule Type : Peptide
Upfront Cash : Undisclosed
January 03, 2023
Lead Product(s) : ST-100
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : AJU Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?